[go: up one dir, main page]

TR199801255T2 - Vitronectin receptor antagonists. - Google Patents

Vitronectin receptor antagonists.

Info

Publication number
TR199801255T2
TR199801255T2 TR1998/01255T TR9801255T TR199801255T2 TR 199801255 T2 TR199801255 T2 TR 199801255T2 TR 1998/01255 T TR1998/01255 T TR 1998/01255T TR 9801255 T TR9801255 T TR 9801255T TR 199801255 T2 TR199801255 T2 TR 199801255T2
Authority
TR
Turkey
Prior art keywords
receptor antagonists
vitronectin receptor
formula
vitronectin
osteporosis
Prior art date
Application number
TR1998/01255T
Other languages
Turkish (tr)
Inventor
El-Fehail Ali Fadia
Edward Bondinell William
M. Keenan Richard
Wen-Fu Ku Thomas
Henry Miller William
Samanen James
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of TR199801255T2 publication Critical patent/TR199801255T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

Formül (I) bilesimleri olan ve osteporoz tedavisinde yararli olan vitronektin reseptör antagonistleri kapsanmistir.(formül).Vitronectin receptor antagonists, which are compounds of formula (I) and useful in the treatment of osteporosis, are included (formula).

TR1998/01255T 1995-12-29 1996-12-20 Vitronectin receptor antagonists. TR199801255T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US953295P 1995-12-29 1995-12-29

Publications (1)

Publication Number Publication Date
TR199801255T2 true TR199801255T2 (en) 1998-10-21

Family

ID=21738237

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/01255T TR199801255T2 (en) 1995-12-29 1996-12-20 Vitronectin receptor antagonists.

Country Status (16)

Country Link
EP (1) EP0895475A4 (en)
JP (1) JP2000502708A (en)
KR (1) KR19990076876A (en)
CN (1) CN1209060A (en)
AU (1) AU1353897A (en)
BR (1) BR9612378A (en)
CA (1) CA2241724A1 (en)
CZ (1) CZ203798A3 (en)
HU (1) HUP9901116A2 (en)
IL (1) IL125034A0 (en)
MX (1) MX9805253A (en)
NO (1) NO983002L (en)
PL (1) PL327919A1 (en)
TR (1) TR199801255T2 (en)
WO (1) WO1997024122A1 (en)
ZA (1) ZA9610855B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0777657A1 (en) * 1994-08-22 1997-06-11 Smithkline Beecham Corporation Bicyclic compounds
WO1997026250A1 (en) * 1996-01-16 1997-07-24 Merck & Co., Inc. Integrin receptor antagonists
DE69716900T2 (en) * 1996-04-10 2003-07-03 Merck & Co., Inc. Alpha v Beta 3 ANTAGONISTS
US20030125317A1 (en) 1996-10-02 2003-07-03 Smithkline Beecham Corporation Vitronectin receptor antagonists
DE19653645A1 (en) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin receptor antagonists, their preparation and their use
DE19653647A1 (en) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin receptor antagonists, their preparation and their use
US6482821B2 (en) 1996-12-20 2002-11-19 Hoechst Aktiengellschaft Vitronectin receptor antagonists, their preparation and their use
US6218387B1 (en) 1996-12-20 2001-04-17 Hoechst Aktiengesellschaft Vitronectin receptor anatagonists, their preparation and their use
CA2297910A1 (en) * 1997-07-25 1999-02-04 Smithkline Beecham Corporation Vitronectin receptor antagonist
JP2002508323A (en) * 1997-12-17 2002-03-19 メルク エンド カムパニー インコーポレーテッド Integrin receptor antagonist
PE20000323A1 (en) * 1998-03-10 2000-05-24 Smithkline Beecham Corp VITRONECTIN RECEPTOR ANTAGONISTS
AU760771B2 (en) * 1998-04-01 2003-05-22 Janssen Pharmaceutica N.V. PDE IV inhibiting pyridine derivatives
GB9812088D0 (en) * 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
SE9803518D0 (en) * 1998-10-15 1998-10-15 Astra Pharma Prod Novel compounds
AU747503B2 (en) 1999-02-03 2002-05-16 Merck & Co., Inc. Benzazepine derivatives as alpha-V integrin receptor antagonists
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
MXPA02000722A (en) 1999-07-21 2002-07-22 Wyeth Corp Bicyclic antagonists selective for the alpha;v.
EG24179A (en) * 1999-09-07 2008-09-28 Smithkline Beecham Corp Vitronectin receptor antagonists
DE10028575A1 (en) 2000-06-14 2002-03-14 Basf Ag integrin
FR2800067B1 (en) * 1999-10-21 2004-12-17 Rhodia Chimie Sa INTERMEDIATES FOR THE MANUFACTURE OF A BENZOFURANE OR NITROGEN BENZOTHIOPHENE DERIVATIVE IN POSITION 5 AND THEIR USES
FR2820743B1 (en) 2001-02-09 2005-02-25 Pf Medicament SYNTHESIS METHOD AND INTERMEDIARIES FOR THE PREPARATION OF PYRIDIN-2-YL-METHYLAMINE DERIVATIVES
CA2444821C (en) 2001-04-24 2012-07-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using anti-angiogenic agents and tnfa
JP4800216B2 (en) * 2003-10-24 2011-10-26 エグゼリクシス， インコーポレイテッド p70S6 kinase modulator and methods of use
AU2005231507B2 (en) 2004-04-08 2012-03-01 Targegen, Inc. Benzotriazine inhibitors of kinases
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006041046A1 (en) * 2004-10-13 2006-04-20 Sankyo Company, Limited Pyridine derivative
BRPI0610506A2 (en) 2005-04-20 2010-06-29 Johnson & Johnson fluoridated pyridine n-oxide thrombin modulators and process for n-oxidation of nitrogen-containing heteroaryls
HUE028987T2 (en) 2005-11-01 2017-01-30 Targegen Inc BI-aryl-meta-pyrimidine inhibitors of kinases
EA201200560A1 (en) 2006-01-18 2012-09-28 Мерк Патент Гмбх SPECIFIC THERAPY USING INTEGRINE LIGANDS FOR CANCER TREATMENT
TW200811164A (en) * 2006-05-12 2008-03-01 Jerini Ag New heterocyclic compounds for the inhibition of integrins and use thereof
EP2441464B1 (en) 2007-01-18 2014-04-09 Merck Patent GmbH Integrin ligands for use in treating colon cancer
EP2730282A1 (en) 2007-11-08 2014-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
US8648066B2 (en) 2009-05-22 2014-02-11 Exelixis, Inc. Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture
EP2445534A2 (en) 2009-05-25 2012-05-02 Merck Patent GmbH Continuous administration of cilengitide in cancer treatments
WO2011082967A1 (en) * 2009-12-17 2011-07-14 Basf Se Method for producing higher ethanolamines
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
MX2016015467A (en) 2014-05-30 2017-03-23 Pfizer Carbonitrile derivatives as selective androgen receptor modulators.
MA45244A (en) 2016-06-13 2019-04-17 Cancer Research Tech Ltd SUBSTITUTED PYRIDINES USED AS DNMT1 INHIBITORS
EP3589627A4 (en) * 2017-02-28 2020-08-05 Morphic Therapeutic, Inc. INHIBITORS OF (ALPHA-V) (BETA-6) -INTEGRIN
EP3760202A1 (en) 2017-02-28 2021-01-06 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
PL3844162T3 (en) 2018-08-29 2025-06-09 Morphic Therapeutic, Inc. Inhibitors of alpha v beta6 integrin
EP3617206A1 (en) 2018-08-29 2020-03-04 Morphic Therapeutic, Inc. Integrin inhibitors
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3627754A (en) * 1970-05-13 1971-12-14 Hoffmann La Roche Process for preparing 7-lower alkanoyl benzodiazepines utilizing ceric salts
JP3497164B2 (en) * 1991-06-28 2004-02-16 スミスクライン・ビーチャム・コーポレイション Bicyclic fibrinogen antagonist
WO1994014776A2 (en) * 1992-12-21 1994-07-07 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
ZA955391B (en) * 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
ZA9610853B (en) * 1995-12-29 1998-04-06 Smithkline Beecham Corp Processes and intermediates for preparing pharmaceuticals.
CZ203898A3 (en) * 1995-12-29 1999-03-17 Smithkline Beecham Corporation Antagonist of vitronectin receptor, pharmaceutical composition containing thereof, process of its preparation and use

Also Published As

Publication number Publication date
JP2000502708A (en) 2000-03-07
AU1353897A (en) 1997-07-28
EP0895475A4 (en) 2000-08-23
KR19990076876A (en) 1999-10-25
ZA9610855B (en) 1997-11-24
CN1209060A (en) 1999-02-24
NO983002L (en) 1998-08-26
EP0895475A1 (en) 1999-02-10
WO1997024122A1 (en) 1997-07-10
CA2241724A1 (en) 1997-07-10
HUP9901116A2 (en) 2000-03-28
NO983002D0 (en) 1998-06-26
CZ203798A3 (en) 1998-12-16
MX9805253A (en) 1998-10-31
PL327919A1 (en) 1999-01-04
IL125034A0 (en) 1999-01-26
BR9612378A (en) 1999-07-13

Similar Documents

Publication Publication Date Title
TR199801255T2 (en) Vitronectin receptor antagonists.
TR199801253T2 (en) Vitronectin receptor antagonists.
ATE314371T1 (en) SPIRO-INDOLE AS Y5 RECEPTOR ANTAGONISTS
SE9702773D0 (en) Novel compounds
GB9514473D0 (en) Chemical compounds
TR199901653T2 (en) Phthalazinones.
UY34152A (en) ? SUBSTITUTED OXAZOLIDINONES AND ITS USE ?.
DE69616480D1 (en) PIPERIDE DERIVATIVES AS NEUROKININANTAGONISTS
DK1200418T3 (en) Nematodicidal trifluorobutene
MX9700557A (en) DIHYDROBENZOFURANES.
TR200001012T2 (en) Novel aryloxy-alkyl-dialkylamines.
TR199800077T1 (en) Controlled release paroxetine preparations.
DK0889886T3 (en) Novel, 6-position substituted phenanthridines
IT1285770B1 (en) CORTICOID COMPOUNDS
MXPA03002911A (en) Chemical compounds.
ATE203519T1 (en) QUINOLINE DERIVATIVES AS ANTIMALARIATIC AGENTS
FI955118A0 (en) Herbicidal substituted 1-phenyl or 1-pyridinyl benzotriazoles
SE9802937D0 (en) Novel compounds
DE69426452D1 (en) FIBRINOGEN RECEPTOR ANTAGONISTS
TR200001102T2 (en) Substituted tetrahydropyrimidinene derivatives, their production and uses.
ATE228760T1 (en) THROMBIN INHIBITORS
TR199701298T1 (en) Tetralins.
TR199800152T1 (en) Endothelin Receptor Antagonists
ATE269313T1 (en) TRYPTASE INHIBITORS
FR2707990B1 (en) New nitrones usable for trapping free radicals.